It has long been acknowledged that pharmaceutical companies can have positive impacts on human rights, particularly the right to health. The development of vaccines for the novel coronavirus after the year of COVID-19 pandemic hitting Indonesia and the rest of the world is just one of the positive impacts that the industry has offered. Yet, the activities of the pharmaceutical industry itself are not without their own human rights risks.
It is therefore important to ensure those pharmaceutical companies respect human rights from production process right through to their products being consumed by the customer.
In this light, human rights due diligence needs to be carried out as the core of corporate responsibility, being enshrined as part of the second pillar of United Nations Guiding Principles on Business and Human Rights (UNGPs). The guidelines aim to prevent and address human rights impacts resulting from company activities.
Following the previous discussion with the representatives of government, academics and pharmaceutical companies, FIHRRST, supported the Ministry of Health and TIFA Foundation, has developed Guidelines for Human Rights Due Diligence for the Pharmaceutical Industry. The guidelines will be launched through a zoom meeting on:
Day, Date : Tuesday, 2 March 2021
Time : 13.30 - 15.00 WIB
For registering on the event, please contact: email@example.com